Study end points and event classification
Bleeding complications were categorized as major, minor, or nuisance. Major and minor bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) study 7 group criteria and criteria used in Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC). 8 Nuisance bleeding, described in neither TIMI nor EPIC, was defined as any clinically documented bleeding complication that did not meet the criteria of either major or minor bleeding. Examples of nuisance bleeding included hematoma that was <5 cm in diameter and mucocutaneous bleeding that lasted <20 minutes.
Our predefined primary study end point was the combined incidence of non-coronary artery bypass grafting (CABG)-related major and minor bleeding complications. Secondary study end points included the incidences of major bleeding, minor bleeding, all bleeding, and the requirement for non-CABG-related blood product transfusion.
Net blood loss was estimated by use of criterion modified by EPIC 9 but first established by Landefeld et al. 10 It was calculated by the addition of the number of units of packed red blood cells transfused to the baseline-minus-nadir hemoglobin. Decision to transfuse was at the discretion of the treating physicians.
All bleeding events were subclassified according to location: vascular access site, intracranial, gastrointestinal, genitourinary, respiratory, and musculomucocutaneous. Retroperitoneal bleeding resulting from femoral artery punctures was classified as vascular access bleeding. Vascular access applied to only arterial punctures, such as access for sheath placement during either PTCA or intra-aortic balloon pump (IABP) insertion. Bleeding from venous access was classified as mucocutaneous bleeding. Intracranial bleeding required documentation of a new neurologic deficit with computerized tomographic evidence of blood density.
Data abstraction
Bleeding events were identified through retrospective detailed chart reviews including both physicians' and nurses' notes from the time of the index infarction until discharge. Laboratory data were obtained by a search through either charted printouts or centralized computerized records. A predesigned standardized data abstraction form was used for data collection.
Thrombolysis and interventional procedure
Patients received either full-dose accelerated tissue plasminogen activator (tPA) or streptokinase according to standard protocols. 11 Patients might subsequently receive further doses of thrombolytics, which might be either full doses or half doses. Both the choice of thrombolytics and the dose used in repeated thrombolysis were at the discretion of the treating physicians.
Abciximab was administrated intravenously as a 0.25 mg/kg bolus, followed by an infusion of 0.125 µg/kg/min for 12 hours. The decision to use abciximab and the choice of dose were at the discretion of the interventional cardiologists. Boluses of heparin of 100 U/kg (without abciximab) or 70 U/kg (with abciximab) were given at the discretion of the cardiologists to obtain an activated clotting time (ACT) of at least 200 to 300 seconds during PTCA. In one center where ACT was not used, empiric weight-adjusted boluses of heparin were given. The use of and the duration of post PTCA heparin were also left at the discretion of the cardiologists. Femoral vascular access sheaths were pulled at least 4 hours after the last dose of procedural heparin. When heparin was continued after the procedure, the sheaths were removed only after intravenous heparin was stopped for at least 4 hours.
Statistical analyses
Continuous variables were presented as medians with 25th and 75th percentiles. Categorical variables were presented as percentages. Missing values accounted for <2% of data fields collected. Comparisons of continuous variables were made by the Wilcoxon rank-sum test. Comparisons of categorical variables and outcomes were made by the Cochran-Mantel-Haenszel chi-square test, adjusted by Yates' continuity correction, or by the Fisher exact test if low expected event rates were encountered. Two-tailed tests were used.
Time-to-event analysis based on the Kaplan-Meier method was used to report our primary study end point. Comparison between the treatment and control groups was made with use of the log-rank statistic. A multivariable Cox proportional hazards model was constructed to calculate the hazard ratio of combined major and minor bleeding associated with abciximab use while adjusting for 11 clinical and procedural variables that we hypothesized a priori by judgment to affect the bleeding risk (see below). Cases with missing data for the candidate variables were excluded listwise. The risk ratio and the two-sided 95% confidence limit were calculated on the basis of maximum likelihood method. Patients were censored at the time of discharge to home or transfer back to their referring hospitals. All analyses were conducted with SPSS 10.0 (SPSS, Chicago, Ill). 12 
Results
Of the 147 patients included in this study, 57 patients (39%) received abciximab, and 90 (61%) did not and were designated as controls.
Clinical and procedural characteristics
Clinical characteristics were similar between the two groups, except for a higher prevalence of pre-existing hypertension in the control group (Table I) . Overall, a high proportion (30%) of patients presented in Killip class III or IV. tPA was used in 89% of the cases, and 16% of all patients received multiple doses of thrombolytics before the index PTCA. Aspirin (ASA) and preprocedural heparin were used in 99% and 97% of all patients, respectively.
Overall, 70% of all patients underwent rescue PTCA, whereas the remaining 30% underwent urgent PTCA (Table II) . There was no difference between the abciximab-treated patients and controls in the time between thrombolysis and PTCA. The numbers (percentages) of patients who underwent PTCA within 12 hours, between 12 and 24 hours, and between 24 and 48 hours after the index thrombolysis were 99 (67%), 24 (16%), and 24 (16%), respec-tively. PTCA was successful in 89% of the procedures attempted, with no difference between the two groups. Total procedural heparin dose per weight was lower in the abciximab group than in the controls (63 U/kg vs 81 U/kg, P = .001), resulting in a lower maximal ACT attained during the procedure in the treatment group compared with the control group (283 seconds vs 342 seconds, P = .005). Stents were used more often in the abciximab group than in the control group (79% vs 51%, P = .001). There was no difference in the use of IABP support periprocedure between the two groups. Early sheath removal, defined as removal ≤12 hours after PTCA or before abciximab infusion was completed, was more common in the abciximab group compared with controls (39% vs 17%, P = .01).
The proportion of patients who received heparin after PTCA was lower in the abciximab group than in the control group (49% vs 86%, P < .001). Of those who received heparin after PTCA, there was no difference in the proportion of patients who received heparin beyond 12 hours after PTCA (81% vs 83%). In contrast, the proportion of patients who were prescribed ticlopidine or clopidogrel was higher in the abciximab group than in the control group (75% vs 54%, P = .02). The use of postprocedural ASA (91% vs 91%) or warfarin (23% vs 39%) did not differ statistically between the groups.
Bleeding complications
A total of 108 bleeding events (10 major, 65 minor, 33 nuisance) occurred in 91 patients (62%). The combined major and minor bleeding complications, the primary end point of our study, occurred significantly more frequently in the abciximab group (63%) than in the controls (39%), with an unadjusted relative risk of 1.6 (P = .004). There were also higher incidences of major bleeding (12% vs 3%, relative risk = 3.68, P = .04) as well as minor bleeding (54% vs 38%, relative risk = 1.4, P = .05) in the treatment group compared with controls ( Figure 1 ). There was, however, no difference in the incidence of nuisance bleeding between the two groups. There was a higher incidence of all bleeding complications in the abciximab group than in the controls (74% vs 54%, relative risk = 1.4, P = .02). The majority (93%) of the major and minor bleeding events occurred within the first 72 hours after infarction (Figure 2) . Among patients who underwent rescue PTCA, the incidences of combined major and minor bleeding (68% vs 34%, relative risk = 2.0, P = .002), major bleeding (18% vs 0%, P = .001), and all bleeding complications (75% vs 49%, relative risk = 1.5, P = .02) were also higher in the abciximab group compared with controls. Blood product transfusion rate did not differ between the two groups (Table III) . Overall, 52% of bleeding complications occurred at the site of vascular access, with no difference noted between the two groups (Table III) . There were only two intracranial bleeds-one in each group (2% abciximab vs 1% control, P = 1.0). One patient had the event 10 hours after receiving abciximab (15 hours after tPA). This patient received only 20 U/kg of heparin during PTCA and no postprocedural heparin. The other patient, who did not receive abciximab, had the event 5 days after PTCA (carried out 27 hours after thrombolysis with tPA). This patient received 100 U/kg heparin during the procedure and remained on heparin for 24 hours afterward. There were two fatal bleeding events-one in each group (2% abciximab vs 1% control, P = 1.0). The fatal bleeding event in the abciximab group was an intracranial bleed, whereas the fatal bleeding event in the control group was a gastrointestinal bleed. The median duration of hospital stay did not differ between those patients who had a major or minor bleed and those who had not (6 days vs 6 days).
Hematologic parameters
Despite the difference in clinical bleeding events, net blood loss, as dictated by the Landefeld index, did not differ between the two groups (Table IV) . There was no difference in the proportion of patients whose net blood loss exceeded 3.0 g/dL hemoglobin (9% hematocrit) or 5.0 g/dL hemoglobin (15% hematocrit) between the groups. In fact, there were greater maximal drops in hemoglobin (3.3 g/dL vs 2.8 g/dL, P = .07) Table II . PTCA procedural characteristics
Figure 1
Comparison of the incidences of combined major and minor bleeding, major bleeding, minor bleeding, nuisance bleeding, and all bleeding events between the abciximab and control groups. RR, Relative risk.
Figure 2
Time-to-event curves on the combined major and minor bleeding events for the abciximab and control groups during the first 14 days after myocardial infarction.
and hematocrit (9% vs 8%, P = .04) in the control group compared with abciximab (Table V) , owing to a nonstatistically significant higher incidence of CABG after PTCA in the control group (9% vs 4%). There was no difference in the incidence of moderate thrombocytopenia (defined as <100,000 cells/µL) or severe thrombocytopenia (defined as <50,000 cells/µL) in the abciximab group compared with controls. Both the maximal aPTT and International Normalized Ratio (INR) attained in the first 72 hours after infarction were higher in the control group than in the abciximab group (150 s vs 103 s for aPTT, P = .02; 1.3 vs 1.2 for INR, P = .02).
Adjusted bleeding risk with abciximab
Eleven clinical and procedural factors were used to adjust the bleeding risk associated with abciximab use in a multivariable Cox proportional hazards model (Table V) . Abciximab remained as the most powerful and only significant independent predictor of combined major and minor bleeding in this model, with an adjusted hazard risk ratio of 1.9 (95% confidence interval 1.1-3.7, P = .04).
Discussion

Incidence of bleeding complications
Our study suggests that the use of abciximab independently increases the risk of major and minor bleeding by approximately 2-fold in the setting of rescue or urgent PTCA after full-dose thrombolytic therapy for AMI. These results complement other small observational cohort studies [4] [5] [6] that have assessed the bleeding risks with abciximab after full-dose thrombolysis in this setting. The high incidence of bleeding highlights the potential additive risks of abciximab therapy during PTCA if full-dose thrombolytics (single or multiple doses) have previously been given. We chose to report the combined incidence of major and minor bleeding as our primary end point to avoid any reporting bias as a result of competing risks (ie, the occurrence of a major bleed in a patient would exclude classification of such patient to have a minor, but different, bleed). We also reported all bleeding events that occurred both before and after PTCA (when abciximab might be given) to minimize any selection bias, whereby patients who were prone to have bleeding complications earlier on might otherwise be excluded from our analysis.
Our study sheds light on the bleeding risk with abciximab when used in a high-risk group after full-dose thrombolysis in a real-life clinical practice setting. Furthermore, in 40% of our cases abciximab was administered as bailout rather than preplanned. Although the potential risk was high, most bleeds were minor and of little or no clinical consequence. Although the rate of major bleeding was higher in the abciximab group compared with controls, it was reassuring to observe that within the limitation of our sample size the rates of both intracranial bleed and fatal bleeding events did not differ between the two groups.
It should be noted that the intent of our study was to quantify the bleeding risk with abciximab use after "full-dose" thrombolytic therapy, not the risk of bleeding with abciximab when used as adjunctive therapy with "reduced dose" thrombolysis. Although data exist to suggest an acceptable bleeding risk with abciximab when given concurrently with half-dose thrombolytic therapy, 2,3 the bleeding risk of abciximab when given after full-dose thrombolysis in the setting of rescue or urgent PTCA has only been sparsely documented. In a substudy of 22 patients from EPIC in which abciximab was administrated after full-dose thrombolysis, the incidences of major and minor bleeding complications were 18% and 36%, respectively, in those who received a bolus and infusion of abciximab during PTCA. 6 A second small study also showed that the incidence of major or minor bleeding in 58 patients who received abciximab during rescue PTCA after full-dose thrombolytic therapy was 41%. 5 In the Global Use of Strategies To Open Occluded Coronary Arteries study (GUSTO-III), the incidences of severe and moderate bleeding events were 4% and 16%, respectively, among 83 patients who received abciximab after full-dose reteplase or alteplase. 4 Our results therefore are in concordance with those found by other authors and underlie the significant bleeding risk when abciximab is used as an adjunctive therapy during PTCA after full-dose thrombolytic therapy has been given.
Requirement for blood transfusion
We did not show a difference in blood product transfusion requirements between the abciximab and con- -8) . 13 This was in contrast to the EPIC substudy, 6 which reported a statistically nonsignificant 2-fold higher rate of blood transfusion in those who received a bolus and infusion abciximab compared with placebo (23% vs 9%). However, none of these studies, including our own, had prespecified algorithms for transfusion guidelines, thus limiting any meaningful comparison between these figures.
Changes in hematologic parameters
Abciximab was not associated with increased net blood loss in our study. This lack of association might be expected because net blood loss, a laboratory measure, might not be a specific indicator of clinical bleeding. Changes in hemoglobin or hematocrit might be due to hemodilution or hemoconcentration as well as unrecognized subclinical bleeding. We also could not preclude the possibility that a higher rate of CABGrelated bleeding (an event that would not be counted by definition in this study) in the control group confounded the observed net blood loss compared with the abciximab group. On the other hand, net blood loss might be an overly sensitive 9 indicator of bleeding that might limit the detection of risk difference in any chosen contrast (such as between treatment and control) in the face of thrombolytic therapy.
Study limitations
There are several limitations to our study. First, the use of abciximab was not randomized. Physicians who deemed patients to be at exceptionally high risk of bleeding might choose to either not give abciximab or prescribe a lower dose or no heparin after PTCA in those who received abciximab. This limitation, however, would only bias toward an underestimation of the true risk increase of bleeding with abciximab compared with controls. Second, all bleeding events were identified retrospectively in a nonblinded manner. They would therefore be subjected to recall and reporting biases, whereby patients known to have received abciximab might more likely be examined, investigated, and reported for bleeding events. Third, patients were censored from follow-up once transferred back to their referring hospitals. Bleeding events occurring late after transfer would thus not be reported. However, the majority of bleeding events in our study occurred within the first 72 hours after PTCA, a period when patients would still be under observation in our coronary care units and therefore were not censored. Last, the small number of bleeding events in our cohort limited our ability to adjust for baseline differences between the two groups during the regression modeling without overfitting the data.
In conclusion, we found that the use of abciximab after full-dose thrombolysis for AMI was associated with a 2-fold increase in the risk of major and minor bleeding in patients undergoing rescue or urgent PTCA, despite lower heparin dosing. Most of the bleeding complications were minor and of little or no clinical consequence. The risks of intracranial and fatal bleeding events were low. There was no impact of transfusion requirement by the use of abciximab. Abciximab was an independent predictor of combined major and minor bleeding by multivariable modeling. Despite its limitations, our study quantified the risk of bleeding complications in this high-risk group in a real-life clinical practice setting. This study, together with others, should assist physicians in balancing the risks and benefits when prescribing abcix-
